Core Insights - The report recommends key stocks across various industries for January 2026, highlighting potential investment opportunities based on market trends and company performance [2][3]. Industry Summaries Construction - Shenghui Integration (603163.SH) is a Taiwanese cleanroom engineering service provider and a core supplier for Google's TPU supply chain, poised to benefit from TSMC's expansion in the U.S. with potential orders from TSMC Arizona and multiple North American data centers [2]. Social Services - China Duty Free Group (601888.SH) is expected to benefit from a new cycle in domestic duty-free sales, with a boost from the upcoming consumption peak during the New Year and Spring Festival, leading to improved performance expectations [2]. Electronics - Lante Optics (688127.SH) is experiencing significant growth in its optical prism product line and is collaborating with multiple waveguide manufacturers for AR glasses, indicating strong profit elasticity and expansion potential [2]. Utilities and Environmental Protection - China General Nuclear Power (003816.SZ) is set to benefit from the normalization of nuclear power approvals and improvements in market pricing mechanisms, with expected production increases in Guangdong province [2]. Nonferrous Metals - Zijin Mining (601899.SH) is a leading player in the nonferrous sector, with high profit contributions from gold and copper, and is entering a rapid growth phase in lithium production, making it a highly valued investment opportunity for 2026 [2]. Agriculture, Forestry, Animal Husbandry, and Fishery - Youran Dairy (9858.HK), a global leader in dairy farming, is expected to benefit from rising milk prices and beef price increases, leading to significant performance recovery [2]. Internet - Tencent Holdings (0700.HK) is well-positioned for the AI era, leveraging its ecosystem advantages, with potential growth from e-commerce and AI agent capabilities not yet reflected in current profit forecasts [2]. Pharmaceuticals - WuXi AppTec (603259.SH) is supported by strong performance, order growth, and capital expenditure, with favorable regulatory changes expected to enhance the valuation of the CXO sector [2]. Light Industry - Sun Paper (002078.SZ) is entering a new capacity release phase with significant production increases expected, making it a compelling investment with reasonable valuation metrics [2]. Textiles and Apparel - Anta Sports (2020.HK) is anticipated to benefit from the performance of its premium sports brands, with a favorable valuation and upcoming catalysts from Q4 operational disclosures and the Spring Festival consumption peak [2].

趋势观察 25：CXO 25Q4 趋势观察 20251227 摘要 新签订单金额反映管线增量，预计新增临床前候选化合物（PCC）增长 20%-30%，主要由创新周期驱动的新管线增加所致，预示未来业绩增 长潜力。 临床前毒理实验用猴价格因需求井喷式增长而上涨，目前 CRO 采购价约 12 万元/只，预计将升至 15 万元/只，主要驱动因素为小核酸、ADC 抗 体药等需求增加，独立实验排期已延长至 2026 年 5 月后，反映供需严 重失衡。 开口合同重现，即猴价上涨风险由买方承担，反映行业对未来价格持续 看涨预期，公司可通过延长排期应对供需不平衡，进一步推高价格，增 加企业运营成本。 2025 年第四季度临床 CRO 市场复苏，折扣下限从 4-7 折升至 6-8 折， 表明行业竞争趋缓，订单实现 10%以上增长，药明康德出售临床业务或 因大临床业务竞争力不足，利润率较低。 2025 年第四季度 CDMO 板块表现尚可，跨国企业（MNC）需求强劲， Biotech 公司需求一般，美国市场逐步转好，欧洲市场表现更佳，整体 与第三季度预期差异不大。 Q&A 2025 年第四季度临床前药效研究的趋势如何？ 2025 年 ...

证券研究报告 | 2025年12月26日 | 晨会纪要 | | --- | 行业与公司 | 数据日期:2025-12-25 | 上证综指 | 深证成指沪深 | 300 指数 | 中小板综指 | 创业板综指 | 科创 50 | | --- | --- | --- | --- | --- | --- | --- | | 收盘指数（点） | 3959.62 | 13531.41 | 4642.53 | 14517.25 | 3938.41 | 1349.05 | | 涨跌幅度（%） | 0.47 | 0.33 | 0.18 | 0.70 | 0.69 | -0.22 | | 成交金额（亿元） | 7850.18 | 11395.04 | 3853.56 | 4151.46 | 5262.93 | 448.28 | 【常规内容】 中国神华(601088.SH) 公司快评:千亿规模收购助力未来发展，龙头行稳 致远 中国海油(600938.SH) 公司快评:渤海海域获得亿吨级油田发现，国内油 气持续上产 金融工程 金融工程周报:股指分红点位监控周报-股指期货主力合约贴水幅度收窄 金融工程日报:沪指震荡攀升录得六连阳，商业 ...

| 数据日期:2025-12-25 | 上证综指 | 深证成指沪深 | 300 指数 | 中小板综指 | 创业板综指 | 科创 50 | | --- | --- | --- | --- | --- | --- | --- | | 收盘指数（点） | 3959.62 | 13531.41 | 4642.53 | 14517.25 | 3938.41 | 1349.05 | | 涨跌幅度（%） | 0.47 | 0.33 | 0.18 | 0.70 | 0.69 | -0.22 | | 成交金额（亿元） | 7850.18 | 11395.04 | 3853.56 | 4151.46 | 5262.93 | 448.28 | 【常规内容】 行业与公司 医药生物行业 2025 年 12 月投资策略：推荐关注 CXO 板块 证券研究报告 | 2025年12月26日 | 晨会纪要 | | --- | 中国神华(601088.SH) 公司快评:千亿规模收购助力未来发展，龙头行稳 致远 中国海油(600938.SH) 公司快评:渤海海域获得亿吨级油田发现，国内油 气持续上产 金融工程 金融工程周报:股指分红点位监控周报-股 ...

智通财经APP获悉，国信证券发布研报称，美国国会近日通过2026财年国防授权法案，其中纳入修订版 《生物安全法案》相关条款，中国创新药产业长期竞争力仍受看好。建议关注CXO板块，并留意创新 药海外临床进展。 中国创新药产业已经体现出长期向好的发展趋势，并在近年集中体现在BD交易的爆发式增长。值得注 意的是，对于大部分国产创新药，对外授权通常只是全球开发的起点，合作伙伴在海外的开发进度，以 及后续全球临床数据的读出可以进一步加强产品在全球市场商业化的确定性。 投资策略：推荐关注CXO板块。2025年12月投资组合：A股：迈瑞医疗、药明康德、爱尔眼科、新产 业、惠泰医疗、开立医疗、澳华内镜、艾德生物、爱博医疗、金域医学、鱼跃医疗、南微医学；H股： 康方生物、科伦博泰生物-B、和黄医药、康诺亚-B、三生制药、药明合联、爱康医疗、威高股份。 风险提示：研发失败风险；商业化不及预期风险；地缘政治风险；政策超预期风险。 国信证券主要观点如下： 《生物安全法案》获参、众议院通过，关注CXO板块投资机会 美国时间12月17日，美国参议院以77票赞成、20票反对的表决结果，通过2026财年国防授权法案 （2026NDAA）。此 ...

证券研究报告 | 2025年12月24日 ——医药生物行业2025年12月投资策略 推荐关注CXO板块 行业研究 · 行业投资策略 医药生物 投资评级：优于大市（维持评级） 证券分析师：陈曦炳 0755-81982939 chenxibing@guosen.com.cn S0980521120001 证券分析师：马千里 010-88005445 maqianli@guosen.com.cn S0980521070001 证券分析师：张超 0755-81982940 zhangchao4@guosen.com.cn S0980522080001 证券分析师：彭思宇 0755-81982723 pengsiyu@guosen.com.cn S0980521060003 证券分析师：陈益凌 021-60933167 chenyiling@guosen.com.cn S0980519010002 证券分析师：凌珑 021-60375401 linglong@guosen.com.cn S0980525070003 证券分析师：肖婧舒 0755-81982826 xiaojingshu@guosen.com.cn S0 ...

Group 1: Overview of the Pharmaceutical Industry - The pharmaceutical industry maintained stable revenue around 2.45 trillion yuan from 2023 to 2025, with quarterly revenue stabilizing at approximately 600 billion yuan [1][15] - The biotech sector is expected to achieve over 100 billion yuan in sales by 2025, marking it as a significant growth segment within the pharmaceutical industry [2] - The overall revenue for the pharmaceutical industry in the first three quarters of 2025 was 1.83 trillion yuan, reflecting a year-on-year decline of 1.5% [15][19] Group 2: Innovation in Pharmaceuticals - The innovation drug sector has shown remarkable performance, with biotech companies experiencing over 70% revenue growth in 2023 and 2024, and maintaining around 42% growth in the first three quarters of 2025 [20][21] - The CXO industry is the fastest-growing sub-sector in terms of profit, with a year-on-year increase of 33.4% [20] - The total transaction value for license-out deals in the innovation drug sector reached 920 billion USD in the first three quarters of 2025, providing significant cash flow for domestic innovation drug companies [3][20] Group 3: International Expansion - The global market for innovative drugs is expanding, with license-out transactions expected to exceed 100 billion USD in 2025, capturing nearly half of the global pharmaceutical business development transaction volume [2] - The export of medical devices from China has shown a recovery trend, with a total export value of 355.3 billion yuan in 2024, marking a year-on-year growth of 9.8% [4][7] Group 4: Blood Products Sector - The blood products industry is characterized by high barriers to entry and a stable pricing structure, with the top six companies accounting for 80% of domestic plasma collection [8] - Despite short-term supply-demand disturbances, the blood products sector remains a stable segment within the pharmaceutical industry [8][22] - The industry is currently experiencing a wave of mergers and acquisitions, leading to increased market concentration [8] Group 5: Medical Devices - The domestic medical device bidding market showed a significant recovery, with a total market size exceeding 80 billion yuan in the first half of 2025, reflecting a year-on-year growth of 62.75% [4] - The recovery in international markets has also contributed to the growth of medical device exports, which are expected to continue their upward trend [4][7]

2025 年 12 月 22 日 招银国际环球市场 | 睿智投资 | 行业研究 中国医药 医药 - 估值与业绩的重新平衡 估值与业绩的重新平衡 MSCI 中国医疗指数 2025 年初至今累计上涨 51.9%，跑赢 MSCI 中国指数 24.3%。 近期，医药板块有所回调（MSCI 中国医疗指数 10 月至今回调 14%）。我们认为， 近期的回调主要是估值与预期的消化与再平衡，这将为后续投资创造更优的布局窗 口。展望 2026 年，创新药出海趋势长期将延续，我们将重点关注已出海管线的临床 进展与数据兑现这一核心催化。政策端方面，《生物安全法案》虽已签署生效，但 鉴于其未波及 Medicaid 和 Medicare 的采购且对关联方定义明确，以及中国 CXO 美 国行政机构收入占比较小，我们预计该法案对中国 CXO 企业实质经营影响有限。 估值表 中国 医药 行业 武 煜, CFA (852) 3900 0842 jillwu@cmbi.com.hk 王云逸 (852) 3916 1729 cathywang@cmbi.com.hk 敬请参阅尾页之免责声明 请到彭博 (搜索代码: RESP CMBR )或 htt ...

Investment Rating - The industry investment rating is "Outperform the Market" (预计6个月内，行业指数表现强于市场表现5%以上) [32] Core Insights - The National Healthcare Security Administration issued the "Guidelines for the Establishment of Pricing Projects for Pathological Medical Services (Trial)," which aims to systematically reshape existing pathological pricing projects, focusing on biopsy sampling, sample processing, slice replication, pathological staining, and diagnosis, establishing 28 pricing projects, 3 additional charges, and 2 expansion items. This refined pricing is expected to promote high-quality development in pathology and create new scenarios for the application of artificial intelligence-assisted technologies [4] - The guidelines will standardize the charging for digital pathological slices, solidifying the data foundation for large-scale applications of new scenarios. It includes "providing digital images of pathological slices" as an essential item for various pathological services, reflecting the costs of related resource consumption in pricing [4] - The guidelines also explore suitable forms to respond to the charging demands of artificial intelligence assistance, promoting the early application of AI in the pathology field by including "AI-assisted diagnosis" as an expansion item in the pricing structure [4] - The establishment of separate pricing projects for pathological diagnosis and sample testing emphasizes the value of technical services and supports precise medication guidance [4] Summary by Sections Investment Strategy - The report suggests focusing on innovative pharmaceutical companies with rich pipeline layouts, such as Heng Rui Medicine, BeiGene, and China National Pharmaceutical Group. It also highlights companies with significant single-product potential and price revaluation prospects, such as 3SBio, Kaineng Technology, and Qianhong Pharmaceutical. Additionally, it recommends companies leading in cutting-edge technology platform layouts, such as Dongcheng Pharmaceutical, Yuanda Pharmaceutical, and Kelun-Biotech [6] - In the CXO sector, it notes that R&D investment in pharmaceuticals is steadily increasing, and the innovation environment is expected to improve, suggesting attention to companies like WuXi AppTec, WuXi Biologics, and Boteng Co. [6] - For upstream companies, it indicates that quality enterprises are entering a harvest period with overseas layouts, recommending attention to Aopumai, Baipusais, and Baiyao [6] - In the medical device sector, it mentions that ongoing procurement will continue to advance, with equipment companies gradually digesting channel inventory, suggesting attention to Mindray Medical, United Imaging, and Kaili Medical [6] Industry News - The report highlights several key developments in the industry, including Takeda's TYK2 drug achieving positive results in Phase III studies, Baiyatai's anti-VEGF monoclonal antibody application for market approval, Sanofi's innovative therapy for hypertrophic cardiomyopathy receiving domestic approval, and Enhertu (Trastuzumab Deruxtecan) gaining FDA approval for a new indication [8][12][15][16]

Core Viewpoint - The healthcare sector in mainland China has experienced a pullback due to the results of national medical insurance drug price negotiations and subsequent profit-taking, but the fundamentals remain unchanged, presenting a good entry opportunity for 2026 [1] Group 1: Industry Outlook - The trend of innovative drug licensing is expected to continue, with multiple potential targets and drug forms anticipated to bring new licensing opportunities next year [1] - Key global Phase III clinical data readings for these licensed assets will be crucial for market sentiment and warrant close attention [1] - Geopolitical concerns regarding China's pharmaceutical R&D outsourcing industry (CXO) have peaked, and a stable medical policy environment in China is expected to continue supporting innovation [1] Group 2: Market Recovery - A more moderate drug procurement policy is expected to drive a recovery in the medical device and diagnostics sectors [1] Group 3: Stock Preferences - The company prefers biotechnology and CXO stocks, with top picks including Innovent Biologics (01801), Kelun-Biotech (06990), WuXi AppTec H-shares (02359), WuXi AppTec A-shares (603259.SH), and WuXi Biologics (02268) [1] - The target price for Innovent Biologics has been slightly raised from HKD 110 to HKD 111, maintaining a "Buy" rating, while the target price for WuXi Biologics has increased from HKD 74 to HKD 82, also with a "Buy" rating [1]